Pulmonary Fibrosis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 288 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pulmonary Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H1 2015', provides an overview of the Pulmonary Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pulmonary Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Pulmonary Fibrosis - Overview 11
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 12
Pulmonary Fibrosis - Therapeutics under Development by Companies 13
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 19
Pulmonary Fibrosis - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Pulmonary Fibrosis - Products under Development by Companies 24
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30
Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31
AdAlta Pty Ltd. 31
Aeolus Pharmaceuticals, Inc. 32
AnaptysBio, Inc. 33
Angion Biomedica Corp. 34
Aquinox Pharmaceuticals Inc. 35
Auspex Pharmaceuticals, Inc. 36
Biogen Idec Inc. 37
BiOrion Technologies B.V. 38
Boehringer Ingelheim GmbH 39
Bristol-Myers Squibb Company 40
Carolus Therapeutics, Inc. 41
Celgene Corporation 42
Chong Kun Dang Pharmaceutical Corp. 43
Compugen Ltd. 44
Corridor Pharmaceuticals Inc. 45
Digna Biotech, S.L. 46
Eli Lilly and Company 47
F. Hoffmann-La Roche Ltd. 48
FibroGen, Inc. 49
Five Prime Therapeutics, Inc. 50
Galectin Therapeutics, Inc. 51
GenKyoTex S.A. 52
Gilead Sciences, Inc. 53
GlaxoSmithKline plc 54
HanAll Biopharma Co., Ltd. 55
Histocell S.L. 56
iBio, Inc. 57
IMMD Inc. 58
ImmuneWorks, LLC 59
IntelGenx Corp. 60
InterMune, Inc. 61
Inventiva SAS 62
Kasiak Research Pvt. Ltd. 63
Kyorin Pharmaceutical Co., Ltd. 64
Lanthio Pharma B.V. 65
Lpath, Inc. 66
LTT Bio-Pharma Co., Ltd. 67
MedImmune, LLC 68
Mesoblast Limited 69
miRagen Therapeutics, Inc. 70
Moerae Matrix, Inc. 71
MSM Protein Technologies, Inc. 72
NicOx S.A. 73
Pacific Therapeutics Ltd. 74
Pharmaxis Limited 75
Pluristem Therapeutics Inc. 76
Progenra, Inc. 77
Promedior, Inc. 78
ProMetic Life Sciences Inc. 79
Pulmatrix, Inc. 80
RestorGenex Corporation 81
Rhizen Pharmaceuticals SA 82
Sanofi 83
Therametrics holding AG 84
Vectura Group plc 85
Pulmonary Fibrosis - Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Combination Products 87
Assessment by Target 88
Assessment by Mechanism of Action 92
Assessment by Route of Administration 95
Assessment by Molecule Type 97
Drug Profiles 99
(pentoxifylline + acetylcysteine) - Drug Profile 99
ABC-294640 - Drug Profile 100
AEOL-10150 - Drug Profile 102
AM-0010 - Drug Profile 105
ANG-3070 - Drug Profile 106
ANG-3298 - Drug Profile 107
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 108
AQX-1125 - Drug Profile 109
BB-3 - Drug Profile 111
BMS-986020 - Drug Profile 113
BOT-191 - Drug Profile 114
C-301 - Drug Profile 115
CC-539 - Drug Profile 116
CC-90001 - Drug Profile 117
CG-1011 - Drug Profile 118
CGEN-25009 - Drug Profile 119
CKD-942 - Drug Profile 120
CT-140 - Drug Profile 121
CT-2009 - Drug Profile 122
DB-02901 - Drug Profile 123
disitertide - Drug Profile 124
Drug for Idiopathic Pulmonary Fibrosis - Drug Profile 126
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 127
FG-3019 - Drug Profile 128
FPA-008 - Drug Profile 130
GKT-137831 - Drug Profile 131
GR-MD-02 - Drug Profile 132
HC-016 - Drug Profile 134
HL-156FIB - Drug Profile 135
HR-017 - Drug Profile 136
IBIOCFB-03 - Drug Profile 137
ICG-001 - Drug Profile 138
IMD-1041 - Drug Profile 139
INT-0024 - Drug Profile 140
interferon gamma-1b - Drug Profile 141
ITMN-10534 - Drug Profile 142
ITMN-14440 - Drug Profile 143
ITMN-30162 - Drug Profile 144
IVA-337 - Drug Profile 145
IW-001 - Drug Profile 146
KBP-7018 - Drug Profile 147
lebrikizumab - Drug Profile 148
LP2 - Drug Profile 150
Lpathomab - Drug Profile 151
LT-0011 - Drug Profile 152
LY-2109761 - Drug Profile 153
MGN-4220 - Drug Profile 154
MMI-0100 - Drug Profile 155
Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 156
MSM-735 - Drug Profile 157
MSX-122 - Drug Profile 158
NAS-911 - Drug Profile 160
NCX-466 - Drug Profile 161
nintedanib - Drug Profile 162
Oligonucleotides for Respiratory and Oncology - Drug Profile 166
omipalisib - Drug Profile 167
P-007 - Drug Profile 168
P-17 - Drug Profile 169
P-529 - Drug Profile 171
PBF-1250 - Drug Profile 173
PBI-4050 - Drug Profile 174
phytate sodium - Drug Profile 175
pirfenidone - Drug Profile 176
PRI-724 - Drug Profile 177
PRM-151 - Drug Profile 179
PUR-1500 - Drug Profile 181
PXS-25 - Drug Profile 182
PXS-4820 - Drug Profile 183
PXS-5033-A - Drug Profile 184
PXS-64 - Drug Profile 185
Recombinant Human Follistatin - Drug Profile 186
Refacell-IPF - Drug Profile 187
RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 188
RP-6503 - Drug Profile 189
SAR-156597 - Drug Profile 190
SD-560 - Drug Profile 191
simtuzumab - Drug Profile 192
Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile 194
Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 195
Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 196
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 197
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 198
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 199
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 200
SPL-334 - Drug Profile 201
Stem Cell Therapy for Asthma and Pulmonary Fibrosis - Drug Profile 202
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 203
Stem Cell Therapy for Pulmonary Fibrosis - Drug Profile 204
STX-100 - Drug Profile 205
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 206
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 208
TD-139 - Drug Profile 209
tipelukast - Drug Profile 210
tralokinumab - Drug Profile 212
vismodegib - Drug Profile 214
Pulmonary Fibrosis - Recent Pipeline Updates 217
Pulmonary Fibrosis - Dormant Projects 265
Pulmonary Fibrosis - Discontinued Products 269
Pulmonary Fibrosis - Product Development Milestones 270
Featured News & Press Releases 270
Appendix 280
Methodology 280
Coverage 280
Secondary Research 280
Primary Research 280
Expert Panel Validation 280
Contact Us 281
Disclaimer 281

List of Tables
Number of Products under Development for Pulmonary Fibrosis, H1 2015 18
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 21
Number of Products under Development by Companies, H1 2015 (Contd..1) 22
Number of Products under Development by Companies, H1 2015 (Contd..2) 23
Number of Products under Development by Companies, H1 2015 (Contd..3) 24
Number of Products under Development by Companies, H1 2015 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2015 26
Comparative Analysis by Late Stage Development, H1 2015 27
Comparative Analysis by Clinical Stage Development, H1 2015 28
Comparative Analysis by Early Stage Development, H1 2015 29
Comparative Analysis by Unknown Stage Development, H1 2015 30
Products under Development by Companies, H1 2015 31
Products under Development by Companies, H1 2015 (Contd..1) 32
Products under Development by Companies, H1 2015 (Contd..2) 33
Products under Development by Companies, H1 2015 (Contd..3) 34
Products under Development by Companies, H1 2015 (Contd..4) 35
Products under Development by Companies, H1 2015 (Contd..5) 36
Products under Investigation by Universities/Institutes, H1 2015 37
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2015 38
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 39
Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H1 2015 40
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2015 41
Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 42
Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 43
Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H1 2015 44
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015 45
Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 47
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015 48
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2015 49
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 50
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2015 51
Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 52
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 53
Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H1 2015 54
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2015 56
Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015 57
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 58
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 59
Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 60
Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H1 2015 61
Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 62
Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2015 63
Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2015 64
Pulmonary Fibrosis - Pipeline by IMMD Inc., H1 2015 65
Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H1 2015 66
Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H1 2015 67
Pulmonary Fibrosis - Pipeline by InterMune, Inc., H1 2015 68
Pulmonary Fibrosis - Pipeline by Inventiva SAS, H1 2015 69
Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 70
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 71
Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H1 2015 72
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2015 73
Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 74
Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H1 2015 75
Pulmonary Fibrosis - Pipeline by Mesoblast Limited, H1 2015 76
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015 77
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2015 78
Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H1 2015 79
Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2015 80
Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2015 81
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2015 82
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2015 83
Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2015 84
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2015 85
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 86
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2015 87
Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H1 2015 88
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H1 2015 89
Pulmonary Fibrosis - Pipeline by Sanofi, H1 2015 90
Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H1 2015 91
Pulmonary Fibrosis - Pipeline by Vectura Group plc, H1 2015 92
Assessment by Monotherapy Products, H1 2015 93
Assessment by Combination Products, H1 2015 94
Number of Products by Stage and Target, H1 2015 96
Number of Products by Stage and Mechanism of Action, H1 2015 100
Number of Products by Stage and Route of Administration, H1 2015 103
Number of Products by Stage and Molecule Type, H1 2015 105
Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 224
Pulmonary Fibrosis - Dormant Projects, H1 2015 272
Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2015 273
Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2015 274
Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2015 275
Pulmonary Fibrosis - Discontinued Products, H1 2015 276